11/20/2019  5:30:45 PM Chg. +1.55 Volume Bid5:30:45 PM Ask6:12:05 PM Market Capitalization Dividend Y. P/E Ratio
162.95CHF +0.96% 200,582
Turnover: 31.82 mill.
162.00Bid Size: 80 162.95Ask Size: 70 10.49 bill.CHF 1.24% 68.68

Business description

Vifor Pharma AG (formerly Galenica AG) is a global specialty pharmaceuticals company that researches, develops, produces and markets its own pharmaceutical products and is the partner of choice for innovative, patient-focused solutions. After the spin-off of the Galenica Santé company in April 2017 from Galenica AG, the company consists of Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, its joint company with Fresenius Medical Care; Relypsa; and OM Pharma. Vifor Pharma is a a world leader in the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of iron deficiency. The company also offers a diversified portfolio of prescription medicines as well as over-the-counter (OTC) products. Key brands in the iron treatment portfolio are intravenous products, Ferinject® and Venofer®, and oral product, Maltofer®. Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is a common company of Vifor Pharma Group and Fresenius Medical Care. VFMCRP develops and commercialises innovative, high-quality therapies in nephrology to improve the lives of patients suffering from chronic kidney disease (CKD) worldwide. The company was founded at the end of 2010 and is owned 55% by Vifor Pharma Group (formerly Galenica Group) and 45% by Fresenius Medical Care. US-based biopharmaceutical company Relypsa focuses on the discovery, development and commercialisation of polymeric medicines for patients with often overlooked and undertreated conditions that can be addressed in the gastrointestinal tract. Relypsa’s first product, Veltassa®, was made for treating hyperkalaemia. With its unique expertise in the field of immunology, OM Pharma develops and manufactures infectious diseases/OTX products for respiratory tract infections, lower urinary tract infections, ear care, abdominal distension, chronic obstructive pulmonary disease, chronic venous insufficiency, diabetic retinopathy, haemorrhoids, menometrorrhagia (heavy menstrual bleeding).
 

Management board & Supervisory board

CEO
-
Management board
Colin Bond, Barbara Angehrn, Chris Springer, Dario Eklund, Michael Puri, Patrick Treanor, Stefan Schulze
Supervisory board
Andreas Walde, Dr. Gianni Zampieri, Dr. Romeo Cerutti, Dr. Sue Mahony, Etienne Jornod, Jacques Theurillat, Kim Stratton, Prof. Dr. Michel Burnier
 

Company data

Name: Vifor Pharma AG
Address: Rechenstrasse 37,CH-9014 St. Gallen
Phone: +41-58-8518000
Fax: +41-58-8518001
E-mail: info@viforpharma.com
Internet: www.viforpharma.com/
Industry: Consumer Goods
Sector: Retailers
Sub sector: -
End of financial year: 12/31
Free Float: 54.85%
IPO date: -

Investor relations

Name: Julien Vignot
IR phone: +41-58-8516690
IR Fax: -
IR e-mail: investors@viforpharma.com

Company calendar

CW 11 | 3/12/2020 4th Quarter/Annual Report
 

Main Shareholders

Freefloat
 
54.85%
Martin und Rosmarie Ebner - Patinex AG und BZ Bank Aktiengesellschaft
 
20.40%
Remo und Manuela Stoffel - Priora Services AG
 
13.10%
Alecta pensionsförsäkring, Sweden
 
3.20%
BNP PARIBAS SA
 
3.10%
Norges Bank
 
2.87%
BlackRock, Inc
 
2.48%